SCHEMBL6155568

SCHEMBL6155568

CC(=O)c1cccc(CCl)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.51
MAOA P21397 2/20 0.50
MRGPRX4 Q96LA9 1/20 0.49
ALDH1A1 P00352 1/20 0.46
LMNA P02545 2/20 0.46
IL4I1 Q96RQ9 1/20 0.46
MAPK1 P28482 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
FOLH1 Q04609 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3335985 0.83 LMNA (0.59) MAOBMAOAMRGPRX4ALDH1A1LMNA
SCHEMBL7054964 0.82 MAOB (0.53) MAOBMAOAMRGPRX4ALDH1A1LMNA
SCHEMBL334537 0.82 MAOB (0.53) MAOBMAOAMRGPRX4ALDH1A1LMNA
SCHEMBL1481937 0.82 PRSS1 (0.55) MAOBMAOAMRGPRX4ALDH1A1LMNA
SCHEMBL39676 0.82 TSHR (0.47) MRGPRX4ALDH1A1FOLH1
SCHEMBL29472003 0.82 TSHR (0.47) MRGPRX4ALDH1A1FOLH1
SCHEMBL46680 0.82 FOLH1 (0.66) MRGPRX4MEN1KMT2ANPC1CYP2D6
SCHEMBL28410476 0.82 FOLH1 (0.46) MRGPRX4LMNAMAPK1MEN1KMT2A
SCHEMBL14544564 0.81 SMN1; SMN2 (0.43) MRGPRX4ALDH1A1MAPK1NPC1RAB9A
SCHEMBL7735116 0.81 MAOB (0.49) MAOBMAOAMRGPRX4ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684287-A 4- (3- (Piperidin-4-yl) -1H-pyrazol-5-yl) -1H-pyrrole [2,3-b ] pyridine derivative, and preparation method and application thereof 烟台新药创制山东省实验室 2025-03-25 CN disclosed
CN-118139864-A New compounds 西特瑞治疗有限公司 2024-06-04 CN disclosed
CN-117417245-A Method for synthesizing ketoprofen through pyrolytic aromatization reaction 复旦大学 2024-01-19 CN disclosed
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 CN disclosed
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS C4 THERAPEUTICS, INC. 2023-01-05 US disclosed
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS C4 THERAPEUTICS, INC. 2023-01-05 US disclosed
EP-4054724-A1 BIFUNCTIONAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2022-09-14 EP disclosed
CN-114599428-A Bifunctional compounds 豪夫迈·罗氏有限公司 2022-06-07 CN disclosed
WO-2021086785-A1 BIFUNCTIONAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2021-05-06 WO disclosed
WO-2021086785-A1 BIFUNCTIONAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2021-05-06 WO disclosed
CN-103449946-B Preparation method of alpha-monochlorinated ketone compound UNIV HUANGSHAN 2015-01-14 CN disclosed
WO-2014026881-A1 IMIDAZO[2,1]THIAZOL-3-ONE DERIVATIVES USEFUL AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed
CN-103449946-A Preparation method of alpha-monochlorinated ketone compound UNIV HUANGSHAN 2013-12-18 CN disclosed
CN-101600700-B Novel 2-amino oxazolines as TAAR1 ligands for CNS disorders HOFFMANN LA ROCHE 2013-08-21 CN disclosed
EP-2002834-A1 Aryl and hetaryl amides as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2008-12-17 EP disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed
CN-1245487-A Herbicidal 3-aminocarbonyl-or 3-aminothiocarbonyl-substituted 2-benzoylcyclohexane-1, 3-diones BASF AG (DE) 2000-02-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS ITCH, EGFR, MUC1 MAOB 3298/4885MAOA 3840/4885MRGPRX4 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.